Amicus Therapeutics, Inc. (FOLD)
Listed on NASDAQ • Healthcare / Biotechnology
Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Explore More Data
Key Information
Symbol:
FOLD
CEO:
Bradley L. Campbell
Exchange:
NASDAQ
CIK:
0001178879
Website:
https://amicusrx.com
SEC Filings:
View SEC →
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Price
9.19
Change
0.2
Change %
2.22%
Open
9.05
Previous Close
8.99
High
9.34
Low
8.99
Volume
6,804,610
Market Cap
2,835,111,424
EV/EBITDA
86.43
Capital Structure (Updated: Nov 05 04:00 PM EST)
Shares Outstanding
308,499,614
FloatShares
288,206,897
Float Ratio
93.42%
Shares Short
18,953,170
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
6.19%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
3.2 trading days
Held Percent Insiders
0.71%
Held Percent Institutions
104.60%
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-04 |
| Earnings Call | 2025-11-04 |
| Avg EPS Estimate | 0.13 |
| Low EPS Estimate | 0.1 |
| High EPS Estimate | 0.16 |
| Revenue | |
| Avg Revenue Forecast | 179,765,640 |
| Low Revenue Forecast | 176,200,000 |
| High Revenue Forecast | 184,458,000 |
FOLD Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $230,998,000 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 2.009 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 3.209 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $443,315,008 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
FOLD Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $32,949,000 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $-45,655,000 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $-32,741,124 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 90.37% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | -5.02% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | -6.67% | Net profit margin, which reflects overall profitability. |
FOLD Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 216.99% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $443,315,008 | Used together with cash and EBITDA to assess debt-paying ability. |
FOLD Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 22.10% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for FOLD (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $9.19 | Latest stock trading price |
| Price Target (High) | $21 | Analyst highest expected price |
| Price Target (Low) | $11 | Analyst lowest expected price |
| Price Target (Average) | $15.8 | Average target price across analysts |
| Price Target (Median) | $15.5 | Median of target prices |
| Average Rating Score | 1.5 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | strong_buy | Consensus rating |
| Analyst Coverage Count | 10 | Number of analysts providing estimates |
| Cash Holdings | $230,998,000 | Total cash held by the company |
| Cash per Share | $0.75 | Cash value per outstanding share |
| Total Debt | $443,315,008 | Company's total debt |
| Quick Ratio | 2.009 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 3.209 | Overall short-term liquidity |
| Debt/Equity Ratio | 216.99% | Leverage ratio: Debt / Equity |
| EBITDA | $32,949,000 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $571,160,000 | Total company revenue |
| Revenue per Share | $1.862 | Total revenue divided by shares outstanding |
| Gross Profit | 90.37% | Revenue minus cost of goods sold |
| Return on Assets | 2.00% | Net income / Total assets |
| Return on Equity | -22.62% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 22.10% | Year-over-year revenue growth |
| Gross Margin | 90.37% | Gross profit / Total revenue |
| EBITDA Margin | 5.77% | EBITDA / Revenue |
| Operating Margin | -5.02% | Operating income / Revenue |
| Profit Margin | -6.67% | Net income / Revenue |
| Free Cash Flow | $-32,741,124 | Cash left after capital expenditures |
| Operating Cash Flow | $-45,655,000 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |